RxDoctor Payments Data

Phillip Meredith

Optometrist · Myrtle Beach, SCNPI 1740256841

Payments from drug & device makers

$1,693in general payments, 2019–2025

Across 19 payments — averaging $89.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$454
  • Bausch & Lomb Americas Inc.$365
  • Johnson & Johnson Vision Care, Inc.$274
  • Sight Sciences, Inc.$136
  • Coopervision Inc.$129
  • Tarsus Pharmaceuticals, Inc.$125
  • plus $209 from 4 others
$270in research payments, 2019–2025

Across 7 payments — averaging $38.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Notal Vision, Inc.$270

What the payments were for

  • Food & beverage$1,693100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,693 in reported general payments places this provider in the 65th percentile of 653 optometrist providers in South Carolina.

See all optometrist providers in South Carolina

Medicare billing

Part B allowed, 2024
$74,804
Medicare patients
492
Services billed
3,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine14$10,406
Latanoprost173$1,708
ErythromycinErythromycin Base32$376
Prednisolone Acetate11$364
Brimonidine Tartrate14$339
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha35$334
Timolol Maleate36$211
Azithromycin11$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$72$10,40614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 653 optometrist providers in South Carolina.

Other optometrist in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →